GRADE of Protein subunit RSV vaccines (GSK Arexvy and Pfizer Abrysvo) in older adults

A Grading of Recommendations, Assessment, Development and Evaluation (GRADE) review of the evidence of benefits and harms from protein subunit RSV vaccination (GSK Arexvy and Pfizer Abrysvo) in adults aged ≥60 years was presented to the Advisory Committee on Immunization Practices (ACIP) on June 26, 2024. GRADE evidence type indicates the certainty in estimates from the available body of evidence. Evidence certainty ranges from high certainty to very low certainty.

The policy questions were, "Should all adults aged ≥75 years be recommended to receive a single dose of RSV vaccination?" and "Should adults aged 60–74 years at increased risk of severe RSV disease be recommended to receive a single dose of RSV vaccination?" These policy questions were not specific to RSV vaccine product, but GRADE review was separated by vaccine type* (protein subunit vaccines, mRNA vaccine). On this webpage GRADE for the protein subunit vaccine products (GSK Arexvy and Pfizer Abrysvo) is reviewed.